Merz & Co.

Merz+co. Gmbh & Co.

Arthur Scherm

Dezsoe Peteri

Klaus W Hummel

Dezso Peteri

Wolfgang Schatton

Novel antitumor and antiviral xanthate compounds, a process for their production, pharmaceutical compositions containing said xanthate compounds, and a method of combating viruses and tumors therewith, are disclosed.

Xanthates as antitumor agents

N-oxides of pyridyl carboxylic acid esters of the following formula are described: ##STR1## wherein R is ##STR2## wherein X is a hydrogen atom, straight or branched C.sub.1 -C.sub.5 -alkyl, C.sub.5 -C.sub.12 -cycloalkyl, 1-adamantyl, or cyclohexylacetyl, and wherein Y is a hydrogen atom, straight or branched C.sub.1 -C.sub.5 -alkyl, 2-ethylbenzofuranoyl-3, C.sub.5 -C.sub.12 -cycloalkyl, or 2-[(4-chlorophenoxy)-2-methylpropanoyloxy]ethyl; a process for the manufacture thereof, pharmaceutical compositions containing these compounds, and method of using the same. These compounds are suited for use in the treatment of hyperlipidemas.

Pyridyl N-oxides

Novel antiviral xanthate compounds, a process for their production, pharmaceutical compositions containing said xanthate compounds, and a method of combating viruses therewith, are disclosed.

Xanthates and antiviral use thereof

Novel hypolipidemic nicotinates and related esters, being phenoxy organic compounds, are disclosed, as well as pharmaceutical compositions thereof and method of treating hyperlipidemia therewith.

Certain 4-(1-piperidino)-phenyl-nicotinates

Novel N-(trimethoxybenzyl)-piperazines of the formula: ##STR1## wherein A= ##STR2## wherein R is trifluoromethyl, hydroxy, nitro, halogen, lower-alkyl, or lower-alkoxy;

Method of enhancing circulation with piperazines

Novel N-(trimethoxybenzyl)-piperazines of the formula: ##STR1## wherein R is trifluoromethyl, hydroxy, nitro, halogen, lower-alkyl, or lower-alkoxy;

Piperazine derivatives as circulation-enhancing substances

A spermicidally-active vaginal suppository consisting essentially of a solid water-soluble polymeric material which melts at body temperature, for example, a polyethylene glycol, having dispersed therein minor amounts of a spermicide, for example, p-nonylphenoxypolyethoxyethanol, a foaming agent operative when the suppository is dissolved in aqueous media to generate a foam-forming gas, for example, a mixture of a water-soluble bicarbonate and a solid weak acid, and a foam-stabilizing agent which is characterized by containing a surfactant, which is effective to reduce the surface tension of water to less than 45 dynes per centimeter, for example, sodium lauryl sulfate, and lactalbumin.

Vaginal suppository for contraception, having a predetermined

Certain substituted phenyl esters of nicotinic acid, compositions and

The present application relates to compositions which influence the central nervous system and which are especially useful in the treatment of hyperkinesis and rigidity. These compositions contain as active ingredient 1,3-dimethyl-5-aminoadamantane in the form of the free base or a pharmaceutically-acceptable salt thereof, together with a methylxanthine compound, e.g., caffeine or theophylline, in an amount up to about fifteen milligrams of the methylxanthine compound per each milligram of the 1,3-dimethyl-5-aminoadamantane compound. These compositions are useful in the treatment of central nervous system disorders, particularly of Parkinson's disease, depressions, spasticity, rigidity, hyperkinesis, and the like. The compositions possess unpredictable beneficial properties of a synergistic nature. The application also relates to the treatment of such central nervous system ailments or conditions with a combination of the said two active agents either concurrently or together in the same dosage form or unit.

Central nervous system compositions and method

Certain 1,3,5-trisubstituted adamantane compounds having central nervous system activity, especially anti-Parkinsonism activity, method of preparing same, and pharmaceutical compositions thereof, method of influencing the central nervous system therewith.

Drugs or medicines for influencing the central nervous system

The application discloses a novel improved process for the production of .alpha.-[2-(p-chlorophenoxy)-isobutyl]-.beta.-nicotinoyl glycol ester, a known compound having a lipid-lowering effect, by the reaction of .alpha.-[2-chlorophenoxy)-isobutyryl]-.beta.-ethyl chloride ester with an alkali salt of nicotinic acid, preferably sodium nicotinate, preferably in a high-boiling polar or dipolar aprotic solvent, especially dimethylformamide, most preferably at a temperature of about 120.degree. - 180.degree. C., and most advantageously in refluxing dimethylformamide. An unpredictable increase in yields of the desired product over yields attainable by previously-available processes is thereby obtained.

Growing community of inventors

Bad Homburg, Germany

Arthur Scherm